Related Experiment Video
Updated: Jul 5, 2025
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Combinatorial targeting of telomerase and DNA-PK induces synergistic apoptotic effects against Pre-B acute
Maryam Katoueezadeh1,2, Parisa Maleki1,2, Seyedeh Atekeh Torabizadeh3
1Student Research Committee, Faculty of Allied Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Background:
Due to the high demand for novel approaches for leukemia-targeted therapy, this study investigates the impact of DNA-PK inhibitor NU7441 on the sensitivity of pre-B ALL cells to the telomerase inhibitor MST-312.
Methods:
The study involved NALM-6 cells treated with MST-312 and NU7441, assessing their viability and metabolic activity using trypan blue and MTT assays. The study also evaluated apoptosis, gene expression changes, and DNA damage using flow cytometry, qRT-PCR, and micronucleus assays. The binding energy of MST-312 in the active site of telomerase was calculated using molecular docking.
Results:
The study's findings revealed a synergistic decline in both cell viability and metabolic activity in NALM-6 cells when exposed to the combined treatment of MST-312 and NU7441, and this decrease occurred without any adverse effects on healthy PBMC cells. Furthermore, the combination treatment exhibited a significantly higher induction of apoptosis than treatment with MST-312 alone, as observed through flow cytometry assay. qRT-PCR analysis revealed that this enhanced apoptosis was associated with a notable downregulation of Bcl-2 expression and an upregulation of Bax gene expression. Moreover, the combination therapy decreased expression levels of hTERT and c-Myc genes. The micronucleus assay indicated that the combination treatment increased DNA damage in NALM-6 cells. Also, a good conformation between MST-312 and the active site of telomerase was revealed by docking data.
Conclusions:
The study suggests that simultaneous inhibition of telomerase and DNA-PK in pre-B ALL presents a novel targeted therapy approach.
Insights
Combining telomerase inhibitor MST-312 with DNA-PK inhibitor NU7441 synergistically reduces pre-B acute lymphoblastic leukemia (ALL) cell viability and increases apoptosis. This novel combination therapy shows promise for targeted leukemia treatment without harming healthy cells.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Leukemia-targeted therapy requires novel approaches.
- Pre-B acute lymphoblastic leukemia (ALL) is a significant clinical challenge.
- DNA-PK and telomerase are potential therapeutic targets.
Purpose of the Study:
- To investigate the impact of DNA-PK inhibitor NU7441 on the sensitivity of pre-B ALL cells to telomerase inhibitor MST-312.
- To evaluate the synergistic effects of combined MST-312 and NU7441 treatment on leukemia cells.
- To assess the safety of this combination therapy on healthy peripheral blood mononuclear cells (PBMCs).
Main Methods:
- Treatment of NALM-6 (pre-B ALL) cells with MST-312 and NU7441.
- Assessment of cell viability and metabolic activity (trypan blue, MTT assays).
- Evaluation of apoptosis, gene expression (qRT-PCR), and DNA damage (micronucleus assay).
- Molecular docking to determine MST-312 binding to telomerase.
Main Results:
- Combined MST-312 and NU7441 synergistically decreased NALM-6 cell viability and metabolic activity without affecting PBMCs.
- The combination therapy significantly increased apoptosis, indicated by flow cytometry and altered Bcl-2/Bax gene expression.
- Treatment reduced hTERT and c-Myc expression, increased DNA damage, and showed favorable molecular docking of MST-312 to telomerase.
Conclusions:
- Simultaneous inhibition of telomerase and DNA-PK is a promising novel targeted therapy for pre-B ALL.
- The combination demonstrates efficacy and a favorable safety profile.
- Further investigation into this therapeutic strategy is warranted.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:31The Intrinsic Apoptotic Pathway